Dianthus Therapeutics Inc. DNTH
$79.26
▲ +7.35% 24H
About
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients with severe autoimmune and inflammatory diseases. It designs and delivers novel monoclonal antibodies and biologics with enhanced selectivity, potency, and dosing convenience c…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees78
TickerDNTH
Statistics
Market Cap$4.33B
Revenue (TTM)$2.0M
Net Income-$162.3M
Net Margin-7973.3%
EPS$-4.20
P/E3.30
P/S3126.94
P/B3.47
EV/EBITDA-16.05
ROE-22.7%
Dividend Yield—
Price$79.26
Data: Twelve Data · Revenue = mcap / P/S